OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to ...

India: Researchers have found in a new study that calcium hydroxide remains a valuable intracanal medicament, with improved ...

OKYO Pharma has announced its plans for the next stage of clinical development of urcosimod (formerly OK-101), its lead drug ...

Netherlands: Wearing a valgus knee brace can meaningfully reduce walking-related pain in patients with medial compartment ...

Suicidal ideation was reported by 13.2% of patients with atopic eczema compared with 8.5% of those without atopic eczema.

The Army Reserve is set to lose 90% of its airpower, including units in Colorado Springs. The cuts are driven by Army ...

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll ...

Treatment with UPA led to improvements across axial and peripheral PsA domains over 12 months, while maintaining high rates of treatment persistence.

OKYO Pharma (OKYO) announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from ...

Of note, BP-NETs comprise approximately 20% to 30% of neuroendocrine tumors and the management of metastatic BP-NETs requires ...

Experts writing in a medical journal are sounding the alarm about a little-known drug that's up to 20 times more deadly than ...